Liraglutide Treatment in a Morbidly Obese Adolescent with a MC4R Gene Variant: Side Effects Reduce Success

Basit Öğe Kaydı
dc.authoridÇamtosun, Emine/0000-0002-8144-4409;
dc.authorwosidÇamtosun, Emine/AAE-3945-2020
dc.authorwosidÇiftci, Nurdan/GNM-8116-2022
dc.contributor.authorCamtosun, Emine
dc.contributor.authorAkinci, Ehan
dc.contributor.authorKayas, Leman
dc.contributor.authorCiftci, Nurdan
dc.contributor.authorTekedereli, Ibrahim
dc.date.accessioned2024-08-04T20:10:20Z
dc.date.available2024-08-04T20:10:20Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractVariants of the melanocortin-4 receptor (MC4R) gene are the most common cause of monogenic obesity. It has been shown that, while obesity cannot be controlled with diet and exercise, glucagon-like-peptide-1 receptor agonists (GLP-1 RA) provide weight loss in the short term. In this paper, our experience with liraglutide treatment in an adolescent patient carrying a MC4R gene variant is presented. A female patient was admitted first at the age of 12.5 years with a complaint of progressive weight gain. She had marked excess of appetite since infancy. On physical examination of the pubertal female patient with a body mass index (BMI) of 36.1 kg/m(2) (3.48 standard deviation score), there was no pathological finding except diffuse acanthosis nigricans. Laboratory examinations revealed only insulin resistance. Weight loss was not achieved with lifestyle changes, metformin and orlistat treatments. On genetic examination, a sporadic heterozygous c.206T > G(p.I69R) variant that had been reported previously, was found in MC4R gene. Treatment with the GLP-1 RA, liraglutide, was initiated and a 19.2% reduction was achieved in the body weight and BMI at the end of 32 weeks. However, the patient, whose treatment compliance was disrupted due to significant gastrointestinal complaints, returned to her former weight within a few months (13 weeks) after treatment was stopped. In this case with a known pathogenic variant in MC4R gene, decrease of appetite and weight loss were achieved with liraglutide treatment, but side-effects of this treatment led to discontinuation of therapy. In such cases, there is need for effective and tolerable treatment options.en_US
dc.identifier.doi10.4274/jcrpe.galenos.2021.2021.0158
dc.identifier.endpage229en_US
dc.identifier.issn1308-5727
dc.identifier.issn1308-5735
dc.identifier.issue2en_US
dc.identifier.pmid34584129en_US
dc.identifier.scopus2-s2.0-85160871636en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage225en_US
dc.identifier.trdizinid1177762en_US
dc.identifier.urihttps://doi.org/10.4274/jcrpe.galenos.2021.2021.0158
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1177762
dc.identifier.urihttps://hdl.handle.net/11616/92718
dc.identifier.volume15en_US
dc.identifier.wosWOS:001001916000016en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofJournal of Clinical Research in Pediatric Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMelanocortin-4 receptor defecten_US
dc.subjectobesityen_US
dc.subjecttreatmenten_US
dc.subjectliraglutideen_US
dc.subjectside effecten_US
dc.titleLiraglutide Treatment in a Morbidly Obese Adolescent with a MC4R Gene Variant: Side Effects Reduce Successen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu